Microglial Activation and Chronic Neurodegeneration

Neurotherapeutics

Volumn 7, Issue 4, 2010, Pages 354-365

  Lull, Melinda E ^a   Block, Michelle L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Chronic neurotoxicity; Inflammation mediated neurodegeneration; Microglia; Oxidative stress; Reactive microgliosis

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ARTICLE; CELL ACTIVATION; CELL FUNCTION; DOPAMINERGIC ACTIVITY; HUMAN; MICROGLIA; NERVE CELL LESION; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CHRONIC DISEASE; DOPAMINE; HUMANS; MICROGLIA; MODELS, BIOLOGICAL; NADPH OXIDASE; NEURODEGENERATIVE DISEASES; NEURONS; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 77957028140     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2010.05.014     Document Type: Article

References (180)

1. Block M.L., Hong J.S. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 2007, 35:1127-1132.
2. del Rio-Hortega P. Cytology and cellular pathology of the nervous system 1932, Penfeild Wed, New York.
3. Morris L., Graham C.F., Gordon S. Macrophages in haemopoietic and other tissues of the developing mouse detected by the monoclonal antibody F4/80. Development 1991, 112:517-526.
4. Alliot F., Godin I., Pessac B. Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Brain Res Dev Brain Res 1999, 117:145-152.
5. Rezaie P., Trillo-Pazos G., Greenwood J., Everall I.P., Male D.K. Motility and ramification of human fetal microglia in culture: an investigation using time-lapse video microscopy and image analysis. Exp Cell Res 2002, 274:68-82.
6. Ling E.A., Wong W.C. The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. Glia 1993, 7:9-18.
7. Dalmau I., Vela J.M., Gonzalez B., Finsen B., Castellano B. Dynamics of microglia in the developing rat brain. J Comp Neurol 2003, 458:144-157.
8. Soulet D., Rivest S. Bone-marrow-derived microglia: myth or reality?. Curr Opin Pharmacol 2008, 8:508-518.
9. Mildner A., Schmidt H., Nitsche M., et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci 2007, 10:1544-1553.
10. Geissmann F., Jung S., Littman D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19:71-82.
11. Flugel A., Bradl M., Kreutzberg G.W., Graeber M.B. Transformation of donor-derived bone marrow precursors into host microglia during autoimmune CNS inflammation and during the retrograde response to axotomy. J Neurosci Res 2001, 66:74-82.
12. Hickey W.F., Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 1988, 239:290-292.
13. Streit W.J., Graeber M.B., Kreutzberg G.W. Expression of Ia antigen on perivascular and microglial cells after sublethal and lethal motor neuron injury. Exp Neurol 1989, 105:115-126.
14. Shechter R., London A., Varol C., et al. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med 2009, 6:e1000113.
15. Lawson L.J., Perry V.H., Gordon S. Turnover of resident microglia in the normal adult mouse brain. Neuroscience 1992, 48:405-415.
16. Ajami B., Bennett J.L., Krieger C., Tetzlaff W., Rossi F.M. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci 2007, 10:1538-1543.
17. Alliot F., Lecain E., Grima B., Pessac B. Microglial progenitors with a high proliferative potential in the embryonic and adult mouse brain. Proc Natl Acad Sci U S A 1991, 88:1541-1545.
18. Aloisi F. Immune function of microglia. Glia 2001, 36:165-179.
19. Adams R.A., Bauer J., Flick M.J., et al. The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med 2007, 204:571-582.
20. Hoek R.M., Ruuls S.R., Murphy C.A., et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000, 290:1768-1771.
21. Harrison J.K., Jiang Y., Chen S., et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci U S A 1998, 95:10896-10901.
22. Lawson L.J., Perry V.H., Dri P., Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990, 39:151-170.
23. Davalos D., Grutzendler J., Yang G., et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 2005, 8:752-758.
24. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318.
25. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996, 19:312-318.
26. Graeber M.B., Streit W.J., Kreutzberg G.W. Axotomy of the rat facial nerve leads to increased CR3 complement receptor expression by activated microglial cells. J Neurosci Res 1988, 21:18-24.
27. Colton C.A., Gilbert D.L. Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett 1987, 223:284-288.
28. Hurley S.D., Walter S.A., Semple-Rowland S.L., Streit W.J. Cytokine transcripts expressed by microglia in vitro are not expressed by ameboid microglia of the developing rat central nervous system. Glia 1999, 25:304-309.
29. Si Q., Kim M.O., Zhao M.L., Landau N.R., Goldstein H., Lee S. Vpr- and Nef-dependent induction of RANTES/CCL5 in microglial cells. Virology 2002, 301:342-353.
30. Liu B., Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 2003, 304:1-7.
31. Streit W.J., Graeber M.B., Kreutzberg G.W. Functional plasticity of microglia: a review. Glia 1988, 1:301-307.
32. Streit W.J., Walter S.A., Pennell N.A. Reactive microgliosis. Prog Neurobiol 1999, 57:563-581.
33. Lynch M.A. The multifaceted profile of activated microglia. Mol Neurobiol 2009, 40:139-156.
34. Elkabes S., DiCicco-Bloom E.M., Black I.B. Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function. J Neurosci 1996, 16:2508-2521.
35. Blinzinger K., Kreutzberg G. Displacement of synaptic terminals from regenerating motoneurons by microglial cells. Z Zellforsch Mikrosk Anat 1968, 85:145-157.
36. Graeber MB, Streit WJ. Microglia: biology and pathology. Acta Neuropathol;119:89-105.
37. Zhong Y., Zhou L.J., Ren W.J., et al. The direction of synaptic plasticity mediated by C-fibers in spinal dorsal horn is decided by Src-family kinases in microglia: the role of tumor necrosis factor-alpha. Brain Behav Immun 2010, 24:874-880.
38. Batchelor P.E., Liberatore G.T., Wong J.Y., et al. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci 1999, 19:1708-1716.
39. Batchelor P.E., Porritt M.J., Martinello P., et al. Macrophages and microglia produce local trophic gradients that stimulate axonal sprouting toward but not beyond the wound edge. Mol Cell Neurosci 2002, 21:436-453.
40. Yamada J., Hayashi Y., Jinno S., et al. Reduced synaptic activity precedes synaptic stripping in vagal motoneurons after axotomy. Glia 2008, 56:1448-1462.
41. Trapp B.D., Wujek J.R., Criste G.A., et al. Evidence for synaptic stripping by cortical microglia. Glia 2007, 55:360-368.
42. Siskova Z., Page A., O'Connor V., Perry V.H. Degenerating synaptic boutons in prion disease: microglia activation without synaptic stripping. Am J Pathol 2009, 175:1610-1621.
43. Liao H., Bu W.Y., Wang T.H., Ahmed S., Xiao Z.C. Tenascin-R plays a role in neuroprotection via its distinct domains that coordinate to modulate the microglia function. J Biol Chem 2005, 280:8316-8323.
44. Morgan S.C., Taylor D.L., Pocock J.M. Microglia release activators of neuronal proliferation mediated by activation of mitogen-activated protein kinase, phosphatidylinositol-3-kinase/Akt and delta-Notch signalling cascades. J Neurochem 2004, 90:89-101.
45. Ransohoff R.M., Perry V.H. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009, 27:119-145.
46. Block M.L., Hong J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005, 76:77-98.
47. Graeber M.B., Streit W.J., Kreutzberg G.W. The microglial cytoskeleton: vimentin is localized within activated cells in situ. J Neurocytol 1988, 17:573-580.
48. Oehmichen W., Gencic M. Experimental studies on kinetics and functions of monuclear phagozytes of the central nervous system. Acta Neuropathol Suppl (Berl) 1975, (suppl 6):285-290.
49. Pei Z., Pang H., Qian L., et al. MAC1 mediates LPS-induced production of superoxide by microglia: the role of pattern recognition receptors in dopaminergic neurotoxicity. Glia 2007, 55:1362-1373.
50. Qin L., Li G., Qian X., et al. Interactive role of the toll-like receptor 4 and reactive oxygen species in LPS-induced microglia activation. Glia 2005, 52:78-84.
51. Qin L., Liu Y., Qian X., Hong J.S., Block M.L. Microglial NADPH oxidase mediates leucine enkephalin dopaminergic neuroprotection. Ann N Y Acad Sci 2005, 1053:107-120.
52. Wu X., Block M.L., Zhang W., et al. The role of microglia in paraquat-induced dopaminergic neurotoxicity. Antioxid Redox Signal 2005, 7:654-661.
53. Mao H., Fang X., Floyd K.M., Polcz J.E., Zhang P., Liu B. Induction of microglial reactive oxygen species production by the organochlorinated pesticide dieldrin. Brain Res 2007, 1186:267-274.
54. Mao H., Liu B. Synergistic microglial reactive oxygen species generation induced by pesticides lindane and dieldrin. Neuroreport 2008, 19:1317-1320.
55. Gao H.M., Hong J.S., Zhang W., Liu B. Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J Neurosci 2003, 23:1228-1236.
56. Bamberger M.E., Landreth G.E. Microglial interaction with beta-amyloid: implications for the pathogenesis of Alzheimer's disease. Microsc Res Tech 2001, 54:59-70.
57. Zhang W., Wang T., Pei Z., et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. Faseb J 2005, 19:533-542.
58. Turchan-Cholewo J., Dimayuga F.O., Gupta S., et al. Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation. J Neurochem 2009, 108:202-215.
59. Block M.L., Calderon-Garciduenas L. Air pollution: mechanisms of neuroinflammation and CNS disease. Trends Neurosci 2009, 32:506-516.
60. Moss D.W., Bates T.E. Activation of murine microglial cell lines by lipopolysaccharide and interferon-gamma causes NO-mediated decreases in mitochondrial and cellular function. Eur J Neurosci 2001, 13:529-538.
61. Liu B., Gao H.M., Wang J.Y., Jeohn G.H., Cooper C.L., Hong J.S. Role of nitric oxide in inflammation-mediated neurodegeneration. Ann N Y Acad Sci 2002, 962:318-331.
62. Sawada M., Kondo N., Suzumura A., Marunouchi T. Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res 1989, 491:394-397.
63. Lee S.C., Liu W., Dickson D.W., Brosnan C.F., Berman J.W. Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J Immunol 1993, 150:2659-2667.
64. Wang T., Pei Z., Zhang W., et al. MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. Faseb J 2005, 19:1134-1136.
65. Liu B., Gao H.M., Hong J.S. Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ Health Perspect 2003, 111:1065-1073.
66. Olson E.E., McKeon R.J. Characterization of cellular and neurological damage following unilateral hypoxia/ischemia. J Neurol Sci 2004, 227:7-19.
67. Morioka T., Kalehua A.N., Streit W.J. Characterization of microglial reaction after middle cerebral artery occlusion in rat brain. J Comp Neurol 1993, 327:123-132.
68. Tsuda M., Mizokoshi A., Shigemoto-Mogami Y., Koizumi S., Inoue K. Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia 2004, 45:89-95.
69. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
70. Ziehn M.O., Avedisian A.A., Tiwari-Woodruff S., Voskuhl R.R. Hippocampal CA1 atrophy and synaptic loss during experimental autoimmune encephalomyelitis, EAE. Lab Invest 2010, 90:774-786.
71. Banati R.B., Gehrmann J., Kellner M., Holsboer F. Antibodies against microglia/brain macrophages in the cerebrospinal fluid of a patient with acute amyotrophic lateral sclerosis and presenile dementia. Clin Neuropathol 1995, 14:197-200.
72. Hall E.D., Oostveen J.A., Gurney M.E. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998, 23:249-256.
73. Bell J.E., Arango J.C., Robertson R., Brettle R.P., Leen C., Simmonds P. HIV and drug misuse in the Edinburgh cohort. J Acquir Immune Defic Syndr 2002, 31(suppl 2):S35-S42.
74. Miller K.R., Streit W.J. The effects of aging, injury and disease on microglial function: a case for cellular senescence. Neuron Glia Biol 2007, 3:245-253.
75. Finch G.L., Hobbs C.H., Blair L.F., et al. Effects of subchronic inhalation exposure of rats to emissions from a diesel engine burning soybean oil-derived biodiesel fuel. Inhal Toxicol 2002, 14:1017-1048.
76. Yankner B.A. Amyloid and Alzheimer's disease-cause or effect?. Neurobiol Aging 1989, 10:470-478.
77. Rogers J., Luber-Narod J., Styren S.D., Civin W.H. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging 1988, 9:339-349.
78. McGeer P.L., Itagaki S., Tago H., McGeer E.G. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett 1987, 79:195-200.
79. Yankner B.A., Duffy L.K., Kirschner D.A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990, 250:279-282.
80. Sasaki A., Yamaguchi H., Ogawa A., Sugihara S., Nakazato Y. Microglial activation in early stages of amyloid beta protein deposition. Acta Neuropathol (Berl) 1997, 94:316-322.
81. Meda L., Cassatella M.A., Szendrei G.I., et al. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995, 374:647-650.
82. Banati R.B., Newcombe J., Gunn R.N., et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000, 123(Pt 11):2321-2337.
83. Peterson J.W., Bo L., Mork S., Chang A., Trapp B.D. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001, 50:389-400.
84. Takeuchi H., Wang J., Kawanokuchi J., Mitsuma N., Mizuno T., Suzumura A. Interferon-gamma induces microglial-activation-induced cell death: a hypothetical mechanism of relapse and remission in multiple sclerosis. Neurobiol Dis 2006, 22:33-39.
85. Murphy A.C., Lalor S.J., Lynch M.A., Mills K.H. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun 2010, 24:641-651.
86. Liu Y., Hao W., Letiembre M., et al. Suppression of microglial inflammatory activity by myelin phagocytosis: role of p47-PHOX-mediated generation of reactive oxygen species. J Neurosci 2006, 26:12904-12913.
87. Mack C.L., Vanderlugt-Castaneda C.L., Neville K.L., Miller S.D. Microglia are activated to become competent antigen presenting and effector cells in the inflammatory environment of the Theiler's virus model of multiple sclerosis. J Neuroimmunol 2003, 144:68-79.
88. Jordan C.A., Watkins B.A., Kufta C., Dubois-Dalcq M. Infection of brain microglial cells by human immunodeficiency virus type 1 is CD4 dependent. J Virol 1991, 65:736-742.
89. Speth C., Dierich M.P., Sopper S. HIV-infection of the central nervous system: the tightrope walk of innate immunity. Mol Immunol 2005, 42:213-228.
90. Brabers N.A., Nottet H.S. Role of the pro-inflammatory cytokines TNF-alpha and IL-1beta in HIV-associated dementia. Eur J Clin Invest 2006, 36:447-458.
91. Turchan-Cholewo J., Dimayuga V.M., Gupta S., Gorospe R.M., Keller J.N., Bruce-Keller A.J. NADPH oxidase drives cytokine and neurotoxin release from microglia and macrophages in response to HIV-Tat. Antioxid Redox Signal 2009, 11:193-204.
92. Polazzi E., Contestabile A. Neuron-conditioned media differentially affect the survival of activated or unstimulated microglia: evidence for neuronal control on apoptotic elimination of activated microglia. J Neuropathol Exp Neurol 2003, 62:351-362.
93. McGeer E.G., Klegeris A., McGeer P.L. Inflammation, the complement system and the diseases of aging. Neurobiol Aging 2005, 26(suppl 1):94-97.
94. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57-69.
95. Long-Smith C.M., Sullivan A.M., Nolan Y.M. The influence of microglia on the pathogenesis of Parkinson's disease. Prog Neurobiol 2009, 89:277-287.
96. Boje K.M., Arora P.K. Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death. Brain Res 1992, 587:250-256.
97. Chao C.C., Hu S., Molitor T.W., Shaskan E.G., Peterson P.K. Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol 1992, 149:2736-2741.
98. Frank-Cannon T.C., Alto L.T., McAlpine F.E., Tansey M.G. Does neuroinflammation fan the flame in neurodegenerative diseases?. Mol Neurodegener 2009, 4:47.
99. McCoy M.K., Tansey M.G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008, 5:45.
100. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from Parkinsonian patients. Neurosci Lett 1994, 165:208-210.
101. Blum-Degen D., Muller T., Kuhn W., Gerlach M., Przuntek H., Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995, 202:17-20.
102. Muller T., Blum-Degen D., Przuntek H., Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand 1998, 98:142-144.
103. Nagatsu T., Mogi M., Ichinose H., Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl 2000, 60:277-290.
104. Nagatsu T., Mogi M., Ichinose H., Togari A. Cytokines in Parkinson's disease. J Neural Transm Suppl 2000, 58:143-151.
105. Knott C., Stern G., Wilkin G.P. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 2000, 16:724-739.
106. Sriram K., O'Callaghan J.P. Divergent roles for tumor necrosis factor-alpha in the brain. J Neuroimmune Pharmacol 2007, 2:140-153.
107. Sriram K., Matheson J.M., Benkovic S.A., Miller D.B., Luster M.I., O'Callaghan J.P. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. Faseb J 2006, 20:670-682.
108. Sriram K., Matheson J.M., Benkovic S.A., Miller D.B., Luster M.I., O'Callaghan J.P. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. Faseb J 2002, 16:1474-1476.
109. De Lella Ezcurra AL, Chertoff M, Ferrari C, Graciarena M, Pitossi F. Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation. Neurobiol Dis;37:630-40.
110. Lee J.K., Tran T., Tansey M.G. Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol 2009, 4:419-429.
111. Nimmo A.J., Vink R. Recent patents in CNS drug discovery: the management of inflammation in the central nervous system. Recent Pat CNS Drug Discov 2009, 4:86-95.
112. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol 2009, 8:382-397.
113. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis;37:510-8.
114. Lee J.K., McCoy M.K., Harms A.S., Ruhn K.A., Gold S.J., Tansey M.G. Regulator of G-protein signaling 10 promotes dopaminergic neuron survival via regulation of the microglial inflammatory response. J Neurosci 2008, 28:8517-8528.
115. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
116. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2007, 2:141-151.
117. Czlonkowska A., Kohutnicka M., Kurkowska-Jastrzebska I., Czlonkowski A. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 1996, 5:137-143.
118. Kurkowska-Jastrzebska I., Wronska A., Kohutnicka M., Czlonkowski A., Czlonkowska A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999, 156:50-61.
119. Hurley S.D., O'Banion M.K., Song D.D., Arana F.S., Olschowka J.A., Haber S.N. Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys. Exp Neurol 2003, 184:659-668.
120. Barcia C., Sanchez Bahillo A., Fernandez-Villalba E., et al. Evidence of active microglia in substantia nigra pars compacta of Parkinsonian monkeys 1 year after MPTP exposure. Glia 2004, 46:402-409.
121. Cicchetti F., Brownell A.L., Williams K., Chen Y.I., Livni E., Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 2002, 15:991-998.
122. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999, 46:598-605.
123. Hunot S., Brugg B., Ricard D., et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci U S A 1997, 94:7531-7536.
124. Ouchi Y., Yagi S., Yokokura M., Sakamoto M. Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat Disord 2009, 15(suppl 3):S200-S204.
125. Ouchi Y., Yoshikawa E., Sekine Y., et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005, 57:168-175.
126. Gao H.M., Liu B., Hong J.S. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2003, 23:6181-6187.
127. Block M.L., Wu X., Pei Z., et al. Nanometer size diesel exhaust particles are selectively toxic to dopaminergic neurons: the role of microglia, phagocytosis, and NADPH oxidase. Faseb J 2004, 18:1618-1620.
128. Qin L., Liu Y., Cooper C., Liu B., Wilson B., Hong J.S. Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem 2002, 83:973-983.
129. Gao H.M., Jiang J., Wilson B., Zhang W., Hong J.S., Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 2002, 81:1285-1297.
130. Qin L., Liu Y., Wang T., et al. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem 2004, 279:1415-1421.
131. Paulsen CE, Carroll KS. Orchestrating redox signaling networks through regulatory cysteine switches. ACS Chem Biol;5:47-62.
132. Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med;48:749-62.
133. Babior B.M. Phagocytes and oxidative stress. Am J Med 2000, 109:33-44.
134. Nam H.J., Park Y.Y., Yoon G., Cho H., Lee J.H. Co-treatment with hepatocyte growth factor and TGF-b1 enhances migration of HaCaT cells through NADPH oxidase-dependent ROS generation. Exp Mol Med 2010, 30:270-279.
135. Sun H.N., Kim S.U., Lee M.S., et al. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-dependent activation of phosphoinositide 3-kinase and p38 mitogen-activated protein kinase signal pathways is required for lipopolysaccharide-induced microglial phagocytosis. Biol Pharm Bull 2008, 31:1711-1715.
136. Roy A., Jana A., Yatish K., et al. Reactive oxygen species up-regulate CD11b in microglia via nitric oxide: Implications for neurodegenerative diseases. Free Radic Biol Med 2008, 45:686-699.
137. Wu D.C., Teismann P., Tieu K., et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A 2003, 100:6145-6150.
138. Block M.L. NADPH oxidase as a therapeutic target in Alzheimer's disease. BMC Neurosci 2008, 9(suppl 2):S8.
139. Wu X.F., Block M.L., Zhang W., et al. The role of microglia in paraquat-induced dopaminergic neurotoxicity. Antioxid Redox Signal 2005, 7:654-661.
140. Gao H.M., Liu B., Zhang W., Hong J.S. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J 2003, 17:1954-1956.
141. Won S.Y., Choi S.H., Jin B.K. Prothrombin kringle-2-induced oxidative stress contributes to the death of cortical neurons in vivo and in vitro: role of microglial NADPH oxidase. J Neuroimmunol 2009, 214:83-92.
142. Qian L., Hu X., Zhang D., et al. beta2 Adrenergic receptor activation induces microglial NADPH oxidase activation and dopaminergic neurotoxicity through an ERK-dependent/protein kinase A-independent pathway. Glia 2009, 57:1600-1609.
143. Rodriguez-Pallares J., Rey P., Parga J.A., Munoz A., Guerra M.J., Labandeira-Garcia J.L. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol Dis 2008, 31:58-73.
144. Hur J, Lee P, Kim MJ, Kim Y, Cho YW. Ischemia-activated microglia induces neuronal injury via activation of gp91phox NADPH oxidase. Biochem Biophys Res Commun;391:1526-30.
145. Green S.P., Cairns B., Rae J., et al. Induction of gp91-phox, a component of the phagocyte NADPH oxidase, in microglial cells during central nervous system inflammation. J Cereb Blood Flow Metab 2001, 21:374-384.
146. Wang T., Liu B., Qin L., Wilson B., Hong J.S. Protective effect of the SOD/catalase mimetic MnTMPyP on inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuronal-glial cultures. J Neuroimmunol 2004, 147:68-72.
147. Li Y., Trush M.A. Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen species production. Biochem Biophys Res Commun 1998, 253:295-299.
148. Block M.L., Li G., Qin L., et al. Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: substance P vs. dynorphin. Faseb J 2006, 20:251-258.
149. Konishi H., Tanaka M., Takemura Y., et al. Activation of protein kinase C by tyrosine phosphorylation in response to H2O2. Proc Natl Acad Sci U S A 1997, 94:11233-11237.
150. Guyton K.Z., Gorospe M., Kensler T.W., Holbrook N.J. Mitogen-activated protein kinase (MAPK) activation by butylated hydroxytoluene hydroperoxide: implications for cellular survival and tumor promotion. Cancer Res 1996, 56:3480-3485.
151. Schreck R., Rieber P., Baeuerle P.A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. Embo J 1991, 10:2247-2258.
152. Forman H.J., Torres M. Reactive oxygen species and cell signaling: respiratory burst in macrophage signaling. Am J Respir Crit Care Med 2002, 166:S4-S8.
153. Wang T., Qin L., Liu B., et al. Role of reactive oxygen species in LPS-induced production of prostaglandin E2 in microglia. J Neurochem 2004, 88:939-947.
154. Min K.J., Pyo H.K., Yang M.S., Ji K.A., Jou I., Joe E.H. Gangliosides activate microglia via protein kinase C and NADPH oxidase. Glia 2004, 48:197-206.
155. Pawate S., Shen Q., Fan F., Bhat N.R. Redox regulation of glial inflammatory response to lipopolysaccharide and interferongamma. J Neurosci Res 2004, 77:540-551.
156. Qin L., Wu X., Block M.L., et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462.
157. Gao H.K., Yin Z., Zhou N., Feng X.Y., Gao F., Wang H.C. Glycogen synthase kinase 3 inhibition protects the heart from acute ischemia-reperfusion injury via inhibition of inflammation and apoptosis. J Cardiovasc Pharmacol 2008, 52:286-292.
158. Huh Y., Jung J.W., Park C., et al. Microglial activation and tyrosine hydroxylase immunoreactivity in the substantia nigral region following transient focal ischemia in rats. Neurosci Lett 2003, 349:63-67.
159. McGeer P.L., Schwab C., Parent A., Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol 2003, 54:599-604.
160. Przedborski S., Tieu K., Perier C., Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr 2004, 36:375-379.
161. Wu D.C., Jackson-Lewis V., Vila M., et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002, 22:1763-1771.
162. Liberatore G.T., Jackson-Lewis V., Vukosavic S., et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999, 5:1403-1409.
163. Zhang W., Wang T., Qin L., et al. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. Faseb J 2004, 18:589-591.
164. Feng Z.H., Wang T.G., Li D.D., et al. Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett 2002, 329:354-358.
165. Teismann P., Vila M., Choi D.K., et al. COX-2 and neurodegeneration in Parkinson's disease. Ann N Y Acad Sci 2003, 991:272-277.
166. Levesque S., Wilson B., Gregoria V., et al. Reactive Microgliosis: Extracellular μ Calpain and Microglia-mediated Dopaminergic Neurotoxicity. Brain 2010, 133:808-821.
167. Kim Y.S., Choi D.H., Block M.L., et al. A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. Faseb J 2007, 21:179-187.
168. Zecca L., Zucca F.A., Wilms H., Sulzer D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 2003, 26:578-580.
169. Ling Z., Gayle D.A., Ma S.Y., et al. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov Disord 2002, 17:116-124.
170. Ling Z., Zhu Y., Tong C.W., Snyder J.A., Lipton J.W., Carvey P.M. Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally. Exp Neurol 2006.
171. Carvey P.M., Chang Q., Lipton J.W., Ling Z. Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson's disease. Front Biosci 2003, 8:s826-s837.
172. Gayle D.A., Ling Z., Tong C., Landers T., Lipton J.W., Carvey P.M. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res Dev Brain Res 2002, 133:27-35.
173. Ling Z.D., Chang Q., Lipton J.W., Tong C.W., Landers T.M., Carvey P.M. Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain. Neuroscience 2004, 124:619-628.
174. Niehaus I. Lippopolysaccharides induce inflammation-mediated neurodeheneration in the substantia nigra and the cerebral cortex (A case report). AD/PD 6th International Conference 2003, 1-38.
175. Cunningham C., Campion S., Lunnon K., et al. Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Psychiatry 2009, 65:304-312.
176. Lehnardt S., Massillon L., Follett P., et al. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A 2003, 100:8514-8519.
177. Henry C.J., Huang Y., Wynne A.M., Godbout J.P. Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1beta and anti-inflammatory IL-10 cytokines. Brain Behav Immun 2009, 23:309-317.
178. Godbout J.P., Chen J., Abraham J., et al. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. Faseb J 2005, 19:1329-1331.
179. Gao H.M., Liu B., Zhang W., Hong J.S. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. Faseb J 2003, 17:1957-1959.
180. Carvey P.M., Punati A., Newman M.B. Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transplant 2006, 15:239-250.